Test your knowledge on de novo oligometastatic metastatic HER2+ breast cancer

Which first-line combination therapy was shown to provide benefit for patients with HER2+ metastatic breast cancer in the CLEOPATRA trial?
Doxorubicin, cyclophosphamide, and paclitaxel
Docetaxel, carboplatin, trastuzumab, and pertuzumab
Tucatinib, trastuzumab, and capecitabine
Pertuzumab, trastuzumab, and docetaxel
Patients with oligometastatic breast cancer can have improved survival after receiving curative intent therapy.
True
False
Which of the following is one of the most common adverse events associated with pertuzumab and trastuzumab therapy?
Constipation
Edema
Diarrhea
Peripheral neuropathy
0
{"name":"Test your knowledge on de novo oligometastatic metastatic HER2+ breast cancer", "url":"https://www.quiz-maker.com/QQDVX5OXJ","txt":"Which first-line combination therapy was shown to provide benefit for patients with HER2+ metastatic breast cancer in the CLEOPATRA trial?, Patients with oligometastatic breast cancer can have improved survival after receiving curative intent therapy., Which of the following is one of the most common adverse events associated with pertuzumab and trastuzumab therapy?","img":"https://www.quiz-maker.com/3012/images/ogquiz.png"}
Quiz Maker Logo Make your own Quiz
Powered by: Quiz Maker